Federated Hermes’s Gilead Sciences GILD Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q1
$111M Sell
797,709
-1,831,827
-70% -$257M 0.18% 127
2025
Q4
$323M Sell
2,629,536
-26,296
-1% -$3.2M 0.54% 32
2025
Q3
$295M Sell
2,655,832
-324,814
-11% -$36.9M 0.52% 38
2025
Q2
$330M Sell
2,980,646
-1,885,664
-39% -$201M 0.62% 31
2025
Q1
$545M Sell
4,866,310
-1,575,291
-24% -$163M 1.18% 9
2024
Q4
$595M Sell
6,441,601
-688,145
-10% -$62M 1.3% 6
2024
Q3
$598M Buy
7,129,746
+808,579
+13% +$61.7M 1.31% 6
2024
Q2
$434M Buy
6,321,167
+1,036,932
+20% +$69.2M 1.03% 10
2024
Q1
$387M Buy
5,284,235
+1,496,880
+40% +$115M 0.89% 16
2023
Q4
$307M Buy
3,787,355
+175,925
+5% +$13.7M 0.76% 23
2023
Q3
$271M Buy
3,611,430
+20,799
+0.6% +$1.6M 0.72% 25
2023
Q2
$277M Sell
3,590,631
-2,050,261
-36% -$164M 0.69% 26
2023
Q1
$468M Sell
5,640,892
-1,716,591
-23% -$142M 1.18% 10
2022
Q4
$632M Sell
7,357,483
-779,455
-10% -$61.7M 1.75% 2
2022
Q3
$502M Buy
8,136,938
+161,902
+2% +$10.2M 1.47% 4
2022
Q2
$493M Buy
7,975,036
+1,008,339
+14% +$62.4M 1.34% 5
2022
Q1
$414M Buy
6,966,697
+588,734
+9% +$37.6M 0.94% 11
2021
Q4
$463M Buy
6,377,963
+119,615
+2% +$8.24M 0.86% 12
2021
Q3
$437M Buy
6,258,348
+127,562
+2% +$8.96M 0.83% 14
2021
Q2
$422M Buy
6,130,786
+24,756
+0.4% +$1.65M 0.79% 15
2021
Q1
$395M Buy
6,106,030
+87,287
+1% +$5.63M 0.77% 18
2020
Q4
$351M Buy
6,018,743
+876,362
+17% +$52.9M 0.72% 19
2020
Q3
$325M Buy
5,142,381
+2,936,687
+133% +$204M 0.76% 19
2020
Q2
$170M Sell
2,205,694
-4,930,612
-69% -$378M 0.42% 44
2020
Q1
$534M Buy
7,136,306
+1,526,835
+27% +$106M 1.57% 8
2019
Q4
$365M Buy
5,609,471
+31,684
+0.6% +$2.06M 0.81% 16
2019
Q3
$354M Buy
5,577,787
+5,317,848
+2,046% +$348M 0.87% 20
2019
Q2
$17.6M Sell
259,939
-7,263
-3% -$478K 0.04% 384
2019
Q1
$17.4M Sell
267,202
-20,953
-7% -$1.39M 0.04% 378
2018
Q4
$18M Buy
288,155
+56,053
+24% +$3.92M 0.05% 333
2018
Q3
$17.9M Buy
232,102
+201,089
+648% +$15.2M 0.04% 382
2018
Q2
$2.2M Sell
31,013
-2,892
-9% -$204K 0.01% 974
2018
Q1
$2.56M Sell
33,905
-267,391
-89% -$21.3M 0.01% 865
2017
Q4
$21.6M Buy
301,296
+93,682
+45% +$7.11M 0.06% 238
2017
Q3
$16.8M Buy
207,614
+47,246
+29% +$3.61M 0.05% 288
2017
Q2
$11.4M Sell
160,368
-159,261
-50% -$10.6M 0.03% 373
2017
Q1
$21.7M Sell
319,629
-177,029
-36% -$12.4M 0.06% 274
2016
Q4
$35.6M Sell
496,658
-231,884
-32% -$17.2M 0.11% 160
2016
Q3
$57.6M Sell
728,542
-271,266
-27% -$22M 0.17% 111
2016
Q2
$83.4M Sell
999,808
-388,885
-28% -$34.5M 0.24% 75
2016
Q1
$128M Sell
1,388,693
-393,069
-22% -$35.4M 0.4% 48
2015
Q4
$180M Buy
1,781,762
+38,512
+2% +$4.01M 0.57% 33
2015
Q3
$171M Buy
1,743,250
+8,741
+0.5% +$971K 0.55% 33
2015
Q2
$203M Buy
1,734,509
+130,532
+8% +$14.3M 0.61% 31
2015
Q1
$157M Sell
1,603,977
-22,379
-1% -$2.27M 0.48% 42
2014
Q4
$153M Buy
1,626,356
+236,349
+17% +$24.4M 0.47% 41
2014
Q3
$148M Sell
1,390,007
-83,725
-6% -$8.2M 0.48% 41
2014
Q2
$122M Buy
1,473,732
+22,973
+2% +$1.79M 0.38% 49
2014
Q1
$103M Sell
1,450,759
-307,442
-17% -$24.1M 0.34% 59
2013
Q4
$132M Sell
1,758,201
-183,016
-9% -$12.7M 0.46% 44
2013
Q3
$122M Sell
1,941,217
-1,165,050
-38% -$69.6M 0.47% 43
2013
Q2
$159M Buy
+3,106,267
New +$162M 0.63% 32

Other funds holding GILD

Federated Hermes's GILD Position: Q1 2026 in Review

Federated Hermes reduced its Gilead Sciences (GILD) stake by 70% in Q1 2026, selling an estimated $257M and leaving 797,709 shares worth $111M. The position accounts for 0.18% of the portfolio, ranked #127.

Federated Hermes first reported a position in GILD in Q2 2013 and has held it in 52 quarters since. The position peaked at $632M in Q4 2022. 2,309 funds tracked by Wall St. Rank hold GILD as of Q1 2026.

  • Federated Hermes held 797,709 shares of Gilead Sciences worth $111M as of Q1 2026.
  • Federated Hermes sold 1,831,827 Gilead Sciences shares in Q1 2026, an estimated $257M.
  • Gilead Sciences made up 0.18% of Federated Hermes's portfolio in Q1 2026, its #127 holding.
  • Federated Hermes first reported a position in Gilead Sciences in Q2 2013 and has held it in 52 quarters since.
  • Federated Hermes's Gilead Sciences position peaked at $632M in Q4 2022.
  • 2,309 funds tracked by Wall St. Rank held Gilead Sciences as of Q1 2026.

Based on Federated Hermes's 13F filing for Q1 2026, filed 11 May 2026.